<p>CytomX Therapeutics, Inc.（纳斯达克代码：CTMX - 获取免费报告）在周三的午盘交易中上涨了 5.4%。该公司的股价最高达到 4.44 美元，最后交易价格为 4.4250 美元。在交易中，共成交 631,028 股，较平均交易量 3,327,983 股下降了 81%。该股票此前收盘价为 4.20 美元。</p>
<p>获取 <strong>CytomX Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对 CTMX 股票发表了看法。Cantor Fitzgerald 在 9 月 22 日的报告中开始覆盖 CytomX Therapeutics 的股票。他们给予该公司 “增持” 评级，并设定 6.00 美元的目标价。Wedbush 在 11 月 7 日的报告中重申了 “跑赢大盘” 评级，并对 CytomX Therapeutics 的股票设定了 6.00 美元的目标价。巴克莱在 10 月 21 日的报告中将 CytomX Therapeutics 的目标价从 3.50 美元上调至 6.00 美元，并给予该股票 “增持” 评级。HC Wainwright 在 11 月 11 日的报告中将 CytomX Therapeutics 的目标价从 5.00 美元上调至 10.00 美元，并给予该公司 “买入” 评级。最后，Wall Street Zen 在 11 月 8 日的研究报告中将 CytomX Therapeutics 的评级从 “持有” 下调至 “卖出”。六位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 6.67 美元。</p>
<p><strong>阅读我们最新的 CTMX 股票报告</strong></p>
<h2>CytomX Therapeutics 价格表现</h2>
<p>该公司的 50 日移动平均线为 3.85 美元，200 日移动平均线为 2.91 美元。该公司的市值为 7.5142 亿美元，市盈率为 11.11，贝塔值为 2.37。</p>
<p>CytomX Therapeutics（纳斯达克代码：CTMX - 获取免费报告）在 11 月 6 日最后发布了其财报。这家生物技术公司报告每股收益（EPS）为（0.09 美元），低于分析师的共识预期（0.04 美元）5 美分。CytomX Therapeutics 的净利润率为 24.66%，股本回报率为 44.49%。该公司在本季度的收入为 596 万美元，而分析师预期为 1150 万美元。股票研究分析师预测 CytomX Therapeutics, Inc.在当前财年将发布-0.05 美元的每股收益。</p>
<h2>机构投资者对 CytomX Therapeutics 的看法</h2>
<p>一些对冲基金和其他机构投资者最近对 CTMX 的持仓进行了调整。Financial Engines Advisors L.L.C.在第三季度购买了 CytomX Therapeutics 的新股份，价值约为 440.7 万美元。Jacobs Levy Equity Management Inc.在第三季度购买了 CytomX Therapeutics 的新头寸，价值约为 16.2 万美元。Velan Capital Investment Management LP 在第三季度将其在 CytomX Therapeutics 的持股增加了 6.7%。Velan Capital Investment Management LP 现在拥有该生物技术公司 80,000 股股票，价值 25.5 万美元，此前在上个季度又购买了 5,000 股。Qube Research &amp; Technologies Ltd 在第三季度收购了 CytomX Therapeutics 的新头寸，价值约为 39.1 万美元。最后，Prelude Capital Management LLC 在第三季度购买了 CytomX Therapeutics 的新头寸，价值 65.9 万美元。67.77% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 CytomX Therapeutics</h2>
<p>（获取免费报告）</p>
<p>CytomX Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于基于其专有的 Probody®平台发现和开发下一代治疗药物。该公司设计了在健康组织中保持不活跃但在肿瘤微环境中选择性激活的掩蔽抗体前药。这种方法旨在增强基于抗体的疗法的安全性和耐受性，特别是针对免疫肿瘤学途径的疗法。</p>
<p>CytomX 的管线核心是 Pacmilimab（CX-072），这是一种抗 PD-L1 Probody 治疗，目前正在针对多种实体肿瘤适应症进行临床评估。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 CytomX Therapeutics</li>
<li>特朗普 5000 亿美元的计划正在推动这些每月分红</li>
<li>在 1 月 1 日之前将 1000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>100 万美元在退休后能维持多久？</li>
<li>崩盘前一个月</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元于 CytomX Therapeutics 吗？</h2>
<p>在你考虑 CytomX Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 CytomX Therapeutics 并不在名单上。</p>
<p>虽然 CytomX Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CytomX治疗

<p>CytomX Therapeutics（NASDAQ:CTMX）股价在午盘交易中上涨了 5.4%，达到 4.44 美元。分析师对该股票给予了 “适度买入” 的评级，目标价为 6.67 美元。公司报告的季度每股收益为（-0.09 美元），未达到预期。机构投资者增加了持股比例，目前 67.77% 的股票由他们持有。CytomX 专注于利用其 Probody®平台开发治疗药物，目前 Pacmilimab（CX-072）正在进行临床试验</p>

<p>Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) traded up 5.4% during mid-day trading on Wednesday . The company traded as high as $4.44 and last traded at $4.4250. 631,028 shares changed hands during trading, a decline of 81% from the average session volume of 3,327,983 shares. The stock had previously closed at $4.20.</p>
<div class="lb-trans"><p>CytomX Therapeutics, Inc.（纳斯达克代码：CTMX - 获取免费报告）在周三的午盘交易中上涨了 5.4%。该公司的股价最高达到 4.44 美元，最后交易价格为 4.4250 美元。在交易中，共成交 631,028 股，较平均交易量 3,327,983 股下降了 81%。该股票此前收盘价为 4.20 美元。</p>
</div><p>Get <strong>CytomX Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>CytomX Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts recently weighed in on CTMX shares. Cantor Fitzgerald assumed coverage on shares of CytomX Therapeutics in a report on Monday, September 22nd. They issued an &#34;overweight&#34; rating and a $6.00 price objective for the company. Wedbush restated an &#34;outperform&#34; rating and issued a $6.00 price objective on shares of CytomX Therapeutics in a report on Friday, November 7th. Barclays lifted their target price on CytomX Therapeutics from $3.50 to $6.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, October 21st. HC Wainwright upped their price target on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 11th. Finally, Wall Street Zen cut shares of CytomX Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $6.67.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 CTMX 股票发表了看法。Cantor Fitzgerald 在 9 月 22 日的报告中开始覆盖 CytomX Therapeutics 的股票。他们给予该公司 “增持” 评级，并设定 6.00 美元的目标价。Wedbush 在 11 月 7 日的报告中重申了 “跑赢大盘” 评级，并对 CytomX Therapeutics 的股票设定了 6.00 美元的目标价。巴克莱在 10 月 21 日的报告中将 CytomX Therapeutics 的目标价从 3.50 美元上调至 6.00 美元，并给予该股票 “增持” 评级。HC Wainwright 在 11 月 11 日的报告中将 CytomX Therapeutics 的目标价从 5.00 美元上调至 10.00 美元，并给予该公司 “买入” 评级。最后，Wall Street Zen 在 11 月 8 日的研究报告中将 CytomX Therapeutics 的评级从 “持有” 下调至 “卖出”。六位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 6.67 美元。</p>
</div><p><strong>Read Our Latest Stock Report on CTMX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 CTMX 股票报告</strong></p>
</div><h2>CytomX Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CytomX Therapeutics 价格表现</h2>
</div><p>The firm's fifty day moving average is $3.85 and its 200 day moving average is $2.91. The firm has a market capitalization of $751.42 million, a price-to-earnings ratio of 11.11 and a beta of 2.37.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 3.85 美元，200 日移动平均线为 2.91 美元。该公司的市值为 7.5142 亿美元，市盈率为 11.11，贝塔值为 2.37。</p>
</div><p>CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.05). CytomX Therapeutics had a net margin of 24.66% and a return on equity of 44.49%. The company had revenue of $5.96 million for the quarter, compared to analyst estimates of $11.50 million. Equities research analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CytomX Therapeutics（纳斯达克代码：CTMX - 获取免费报告）在 11 月 6 日最后发布了其财报。这家生物技术公司报告每股收益（EPS）为（0.09 美元），低于分析师的共识预期（0.04 美元）5 美分。CytomX Therapeutics 的净利润率为 24.66%，股本回报率为 44.49%。该公司在本季度的收入为 596 万美元，而分析师预期为 1150 万美元。股票研究分析师预测 CytomX Therapeutics, Inc.在当前财年将发布-0.05 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On CytomX Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 CytomX Therapeutics 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in CTMX. Financial Engines Advisors L.L.C. bought a new stake in shares of CytomX Therapeutics in the 3rd quarter valued at approximately $4,407,000. Jacobs Levy Equity Management Inc. bought a new position in CytomX Therapeutics during the third quarter valued at about $162,000. Velan Capital Investment Management LP increased its holdings in shares of CytomX Therapeutics by 6.7% during the 3rd quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company's stock valued at $255,000 after acquiring an additional 5,000 shares during the last quarter. Qube Research &amp; Technologies Ltd acquired a new position in CytomX Therapeutics during the third quarter valued at approximately $391,000. Finally, Prelude Capital Management LLC bought a new position in CytomX Therapeutics in the 3rd quarter worth $659,000. 67.77% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对 CTMX 的持仓进行了调整。Financial Engines Advisors L.L.C.在第三季度购买了 CytomX Therapeutics 的新股份，价值约为 440.7 万美元。Jacobs Levy Equity Management Inc.在第三季度购买了 CytomX Therapeutics 的新头寸，价值约为 16.2 万美元。Velan Capital Investment Management LP 在第三季度将其在 CytomX Therapeutics 的持股增加了 6.7%。Velan Capital Investment Management LP 现在拥有该生物技术公司 80,000 股股票，价值 25.5 万美元，此前在上个季度又购买了 5,000 股。Qube Research &amp; Technologies Ltd 在第三季度收购了 CytomX Therapeutics 的新头寸，价值约为 39.1 万美元。最后，Prelude Capital Management LLC 在第三季度购买了 CytomX Therapeutics 的新头寸，价值 65.9 万美元。67.77% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About CytomX Therapeutics</h2>
<div class="lb-trans"><h2>关于 CytomX Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.</p>
<div class="lb-trans"><p>CytomX Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于基于其专有的 Probody®平台发现和开发下一代治疗药物。该公司设计了在健康组织中保持不活跃但在肿瘤微环境中选择性激活的掩蔽抗体前药。这种方法旨在增强基于抗体的疗法的安全性和耐受性，特别是针对免疫肿瘤学途径的疗法。</p>
</div><p>At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.</p>
<div class="lb-trans"><p>CytomX 的管线核心是 Pacmilimab（CX-072），这是一种抗 PD-L1 Probody 治疗，目前正在针对多种实体肿瘤适应症进行临床评估。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than CytomX Therapeutics</li>
<li>Trump's $500B plan is fueling these monthly dividends</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>The McDonald's Secret</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 CytomX Therapeutics</li>
<li>特朗普 5000 亿美元的计划正在推动这些每月分红</li>
<li>在 1 月 1 日之前将 1000 美元投入这只股票 [不是 NVDA]</li>
<li>麦当劳的秘密</li>
<li>100 万美元在退休后能维持多久？</li>
<li>崩盘前一个月</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CytomX Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元于 CytomX Therapeutics 吗？</h2>
</div><p>Before you consider CytomX Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 CytomX Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 CytomX Therapeutics 并不在名单上。</p>
</div><p>While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CytomX Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CytomX 治疗（NASDAQ 代码：CTMX）股价上涨 5.4% - 以下是原因